Ticagrelor and prasugrel in acute coronary syndrome: a single-arm crossover platelet reactivity study.
Acute Coronary Syndrome
/ blood
Cross-Over Studies
Drug Monitoring
/ methods
Drug Substitution
/ methods
Female
Humans
Male
Middle Aged
Outcome Assessment, Health Care
Percutaneous Coronary Intervention
/ methods
Platelet Aggregation
/ drug effects
Platelet Aggregation Inhibitors
/ administration & dosage
Platelet Function Tests
/ methods
Prasugrel Hydrochloride
/ administration & dosage
Ticagrelor
/ administration & dosage
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
pubmed:
20
7
2021
medline:
28
12
2021
entrez:
19
7
2021
Statut:
ppublish
Résumé
To compare the degree of platelet inhibition between ticagrelor and prasugrel in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Platelet function was assessed by impedance aggregometry after 30-90 days of therapy with acetylsalicylic acid and ticagrelor and over 15 days after switching to prasugrel. High-on-treatment platelet reactivity (HRPR) was defined for ADP test results above the upper limit of normal. A total of 105 patients were included, 81.9% males and 33.3% people with diabetes, with a mean age of 60.8 ± 8.1 years. Mean platelet reactivity was not significantly different between the two antiplatelet strategies, as the prevalence of HRPR (8.6 vs 12.3%, P = 0.50). Switching between the two antiplatelet agents was safe and well tolerated, and effectively reduced platelet reactivity in over 95% of the patients (only 3.8% of the study population displaying ineffective response to both drugs). Ticagrelor and prasugrel have a similar effect on platelet reactivity. Switching between the two drugs can be safely done.
Identifiants
pubmed: 34280175
doi: 10.2459/JCM.0000000000001222
pii: 01244665-202109000-00003
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Prasugrel Hydrochloride
G89JQ59I13
Ticagrelor
GLH0314RVC
Types de publication
Clinical Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
686-692Informations de copyright
Copyright © 2021 Italian Federation of Cardiology - I.F.C. All rights reserved.
Références
Tantry US, Bonello L, Aradi D, et al. Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62:2261–2273.
Geisler T, Booth J, Tavlaki E, et al. High platelet reactivity in patients with acute coronary syndromes undergoing percutaneous coronary intervention: randomised controlled trial comparing prasugrel and clopidogrel. PLoS One 2015; 10:e0135037.
Alexopoulos D, Xanthopoulou I, Storey RF, et al. Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. Am Heart J 2014; 168:530–536.
Verdoia M, Sartori C, Pergolini P, et al. Novara Atherosclerosis Study Group (NAS). Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation. Vascul Pharmacol 2016; 77:48–53.
Nardin M, Verdoia M, Sartori C, et al. Novara Atherosclerosis Study Group (NAS). Diabetes mellitus, glucose control parameters and platelet reactivity in ticagrelor treated patients. Thromb Res 2016; 143:45–49.
Verdoia M, De Luca G. Advanced age and high residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor: reply. J Thromb Haemost 2016; 14:57–64.
Bonello L, Tantry US, Marcucci R, et al. Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56:919–933.
Azmoon S, Angiolillo DJ. Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. Catheter Cardiovasc Interv 2013; 81:232–242.
Ancrenaz V, Daali Y, Fontana P, et al. Impact of genetic polymorphisms and drug–drug interactions on clopidogrel and prasugrel response variability. Curr Drug Metab 2010; 11:667–677.
Verdoia M, Pergolini P, Nardin M, et al. Prevalence and predictors of high-on treatment platelet reactivity during prasugrel treatment in patients with acute coronary syndrome undergoing stent implantation. J Cardiol 2019; 73:198–203.
Wallentin L, Becker RC, Budaj A, et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045–1057.
Nylander S, Femia EA, Scavone M, et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J Thromb Haemost 2013; 11:1867–1876.
Wiviott SD, Braunwald E, Angiolillo DJ, et al. TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel—Thrombolysis in Myocardial Infarction 38. Circulation 2008; 118:1626–1636.
Motovska Z, Hlinomaz O, Kala P, et al. PRAGUE-18 Study Group. 1-Year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor. J Am Coll Cardiol 2018; 71:371–381.
Sakurai R, Burazor I, Bonneau HN, Kaneda H. Head-to-head comparison of prasugrel versus ticagrelor in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. J Interv Cardiol 2017; 30:457–464.
Verdoia M, Schaffer A, Sartori C, et al. Vitamin D deficiency is independently associated with the extent of coronary artery disease. Eur J Clin Invest 2014; 44:634–642.
Verdoia M, Pergolini P, Camaro C, et al. Novara Atherosclerosis Study Group (NAS). PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty. Blood Coagul Fibrinolysis 2013; 24:411–418.
Vidali M, Rolla R, Parrella M, et al. Role of the laboratory in monitoring patients receiving dual antiplatelet therapy. Int J Lab Hematol 2012; 34:484–494.
De Luca G, Smit JJ, Ernst N, et al. Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost 2005; 93:820–823.
De Luca G, Dirksen MT, Spaulding C, et al. DESERT Cooperation. Time course, predictors and clinical implications of stent thrombosis following primary angioplasty. Insights from the DESERT cooperation. Thromb Haemost 2013; 110:826–833.
Nardin M, Verdoia M, Pergolini P, et al. Novara Atherosclerosis Study Group (NAS). Impact of adenosine A2a receptor polymorphism rs5751876 on platelet reactivity in ticagrelor treated patients. Pharmacol Res 2018; 129:27–33.
Crimi G, De Rosa R, Mandurino-Mirizzi A, et al. De-escalating dual antiplatelet therapy in patients with acute coronary syndromes: the right strategy to harmonize time-dependent ischemic and bleeding risk in elderly patients? J Cardiovasc Med (Hagerstown) 2020; 21:281–285.
Fortuni F, Crimi G, Morici N, et al. Assessing bleeding in acute coronary syndrome using the bleeding academic research consortium definition. J Cardiovasc Med (Hagerstown) 2019; 20:818–824.
Verdoia M, Schaffer A, Barbieri L, et al. Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials. J Cardiovasc Pharmacol 2014; 63:339–350.
Perl L, Lerman-Shivek H, Rechavia E, et al. Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2014; 63:513–517.
Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy 2014; 34:1077–1090.
Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol 2014; 63:2503–2509.
Laine M, Frere C, Toesca R, et al. Ticagrelor versus prasugrelin diabetic patients with an acute coronary syndrome: a pharmacodynamic randomised study. Thromb Haemost 2014; 111:273–278.
Lhermusier T, Voisin S, Murat G, et al. Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity. Int J Cardiol 2014; 174:874–876.
Bassez C, Deharo P, Pankert M, et al. Effectiveness of switching ‘low responders’ to prasugrel to ticagrelor after acute coronary syndrome. Int J Cardiol 2014; 176:1184–1185.
Laine M, Gaubert M, Frere C, et al. COMparison of Platelet reactivity following prAsugrel and ticagrelor loading dose in ST-Segment elevation myocardial infarction patients: the COMPASSION study. Platelets 2015; 26:570–572.
Biondi-Zoccai G, Lotrionte M, Agostoni P, et al. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acutecoronary syndromes. Int J Cardiol 2011; 150:325–331.
Perl L, Zemer-Wassercug N, Rechavia E, et al. Comparison of platelet inhibition by prasugrel versus ticagrelorover time in patients with acute myocardial infarction. J Thromb Thrombolysis 2015; 39:1–7.
Lemesle G, Schurtz G, Bauters C, Hamon M. High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. J Thromb Haemost 2015; 13:931–942.
Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013; 61:1601–1606.
Alexopoulos D, Galati A, Xanthopoulou I, et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 2012; 60:193–199.
Angiolillo DJ, Curzen N, Gurbel P, et al. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel inpatients with stable coronary artery disease: results of the SWAP-2 Study (Switching Anti Platelet-2). J Am Coll Cardiol 2014; 63:1500–1509.
Franchi F, Faz GT, Rollini F, et al. Pharmacodynamic effects of switching from prasugrel to ticagrelor: results of the prospective, randomized SWAP-3 study. JACC Cardiovasc Interv 2016; 9:1089–1098.
Siller-Matula JM, Francesconi M, Dechant C, et al. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol 2013; 167:2018–2023.
Codner P, Vaduganathan M, Rechavia E, et al. Clopidogrel response up to 6 months after acute myocardial infarction. Am J Cardiol 2012; 110:321–325.
Verdoia M, Sartori C, Pergolini P, et al. Immature platelet fraction and high-on treatment platelet reactivity with ticagrelor in patients with acute coronary syndromes. J Thromb Thrombolysis 2016; 41:663–670.